Oral phosphodiesterase type 5 inhibitors and priapism: A VigiBase analysis. Leslie SW, Sooriyamoorthy T, Abbasi B, Shaw NM, et al. Pharmacoepidemiol Drug Saf 2024;33:e5721.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Leslie SW, Sooriyamoorthy T, Abbasi B, Shaw NM, et al. Oral phosphodiesterase type 5 inhibitors and priapism: A VigiBase analysis. Pharmacoepidemiol Drug Saf 2024;33:e5721.
PMID: 37909414